Calidi Biotherapeutics Inc. (NYSE American: CLDI) Is ‘One to Watch’
Calidi’s unique OV platforms are engineered to protect and amplify virus efficacy, enhancing tumor targeting and patient safety. Calidi’s lead programs, CLD-101, CLD-201, and CLD-400, are advancing through key development stages, with major milestones anticipated, including Phase 1b/2 enrollment for CLD-101 in Q1 2025 and Phase 1 trials for CLD-201 expected in 2H 2024. The company targets a $13-15 billion U.S. market across multiple high-need cancer types, including GBM, TNBC and lung cancer. Calidi’s leadership team combines business, scientific and operational expertise, with a track record of successful exits and growth. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology…